Drug
Vadimezan clinical trials
Also written ASA404 and DMXAA.
- studies test it
- 17
- open now
- 0
- in phase 3
- 2
- first study started
- 1995
How studies write it
Studies that test it under each name
Name
Development codes
- ASA404
- 12
Studies by the year they started
17 studies that test it; most in 2010 (7)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 3
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 5
Novartis Pharmaceuticals (10) · Antisoma Research (2) · University of Glasgow (1) · Swiss Group for Clinical Cancer Research (1) · Cancer Research UK (1) · Hoosier Cancer Research Network (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Carboplatin (2) · Paclitaxel (2) · Docetaxel (1) · Cetuximab (1)
Studies
Open first, then newest update. How each study uses vadimezan is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung CancerTerminatedPhase 3Novartis PharmaceuticalsNCT00738387Written as ASA404
- ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung CancerTerminatedPhase 3Novartis PharmaceuticalsNCT00662597Written as ASA404
- An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1Novartis PharmaceuticalsNCT00674102Written as ASA404
- Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid TumorsCompletedPhase 1Novartis PharmaceuticalsNCT01285453Written as vadimezan
- A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal FunctionTerminatedPhase 1Novartis PharmaceuticalsNCT01278758Written as ASA404, DMXAA or DXAA
- An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404TerminatedPhase 1Novartis PharmaceuticalsNCT01240642Written as ASA404
- An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic FunctionTerminatedPhase 1Novartis PharmaceuticalsNCT01278849Written as ASA404
- A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid TumorsTerminatedPhase 1Novartis PharmaceuticalsNCT01299701Written as ASA404
- Second-Line Docetaxel + ASA404 for Advanced Urothelial CarcinomaWithdrawnPhase 2Hoosier Cancer Research NetworkNCT01071928Written as ASA404
- Dimethylxanthenone Acetic Acid in Treating Patients With Solid TumorsCompletedPhase 1University of GlasgowNCT00003697Written as vadimezan
- ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid TumorsWithdrawnPhase 1University of California, San FranciscoNCT01031212Written as ASA404
- Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedPhase 2Swiss Group for Clinical Cancer ResearchNCT01057342Written as vadimezan
- A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor MalignanciesTerminatedPhase 1Novartis PharmaceuticalsNCT01290380Written as ASA404, DMXAA, DXAA
- Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 InhibitorTerminatedPhase 1Novartis PharmaceuticalsNCT01299415Written as Vadimezan™
- Study of DMXAA (Now Known as ASA404) in Solid TumorsCompletedPhase 1Cancer Research UKNCT00863733Written as DMXAA
- Phase I Safety Study of DMXAA in Refractory TumorsCompletedPhase 1Antisoma ResearchNCT00856336Written as DMXAA
- Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate CancerCompletedPhase 2Antisoma ResearchNCT00111618Written as AS1404 (DMXAA)
Codes
What other systems call vadimezan · ClinicalTrials.gg INT003544
- MeSH (NLM) C066668vadimezanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0829J8133HVADIMEZANConfirmed FDA, NLM, Wikidata
- Wikidata Q7908310vadimezanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C2504VadimezanOne source FDA
- DrugBank DB06235One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C066668 | vadimezan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0829J8133H | VADIMEZAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7908310 | vadimezan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C2504 | Vadimezan | One source FDA |
| DrugBank | DB06235 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.